Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GS010 in Leber Hereditary Optic Neuropathy (REFLECT)
NCT03293524Phase 3Completed
- Sponsor
- GenSight Biologics
- Start
- Mar 2018
- Primary completion
- Jul 2024
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 7
01
Overview
A Phase 3 trial of lenadogene nolparvovec in Leber hereditary optic neuropathy (LHON), sponsored by GenSight Biologics. Started Mar 2018; status: completed.
02
Drugs
lenadogene nolparvovec
03
Conditions
Leber hereditary optic neuropathy (LHON)
Beyond the preview
Go deeper on NCT03293524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03293524.